INT14092

From wiki-pain
Revision as of 09:07, 24 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.40
First Reported 1991
Last Reported 2009
Negated 1
Speculated 0
Reported most in Body
Documents 3
Total Number 5
Disease Relevance 2.26
Pain Relevance 1.77

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Serpinb1b) cytoplasm (Serpinb1b)
Anatomy Link Frequency
muscle 1
Serpinb1b (Mus musculus)
Pain Link Frequency Relevance Heat
corticosteroid 75 99.24 Very High Very High Very High
tolerance 20 98.18 Very High Very High Very High
dorsal root ganglion 7 95.48 Very High Very High Very High
antagonist 45 91.04 High High
agonist 72 89.04 High High
action potential duration 6 85.92 High High
Morphine 1 84.80 Quite High
Dynorphin 1 84.04 Quite High
Opioid 5 83.60 Quite High
MU agonist 1 80.48 Quite High
Disease Link Frequency Relevance Heat
Asthma 248 97.00 Very High Very High Very High
Ganglion Cysts 8 95.48 Very High Very High Very High
Airway Obstruction 42 85.88 High High
Overweight 3 71.36 Quite High
INFLAMMATION 29 68.64 Quite High
Vibrio Infection 1 61.32 Quite High
Dyspnea 44 54.24 Quite High
Tremor 3 20.64 Low Low
Suicidal Behaviour 6 20.28 Low Low
Akathisia 3 18.28 Low Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
However as discussed previously, with the regular use of LABAs tolerance is common, resulting in a decrease in duration of protection.93,94 Since LTRAs have shown protection against EIB for 24 hours, how do they compare with LABAs in clinical studies?
Gene_expression (protection) of EIB associated with tolerance
1) Confidence 0.40 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2789687 Disease Relevance 0 Pain Relevance 0.12
Concerns that athletes taking inhaled corticosteroids (ICS) for asthma control may be using medications that increase muscle mass as can be obtained from anabolic steroids have also been dismissed as appropriate doses of ICS have shown the ability to reduce the severity of EIB without this or other adverse effects.7
Gene_expression (severity) of EIB in muscle associated with asthma and corticosteroid
2) Confidence 0.40 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2789687 Disease Relevance 0.65 Pain Relevance 0.26
When spirometry is not available, a therapeutic trial of a medication which should be effective in EIB may be enough to make the diagnosis.
Gene_expression (effective) of EIB
3) Confidence 0.40 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2789687 Disease Relevance 0.35 Pain Relevance 0
Specifically, it is approved for the prevention of EIB from 2 years of age (Pajaron-Fernandez et al 2006).
Neg (prevention) Gene_expression (prevention) of EIB
4) Confidence 0.03 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376066 Disease Relevance 0.61 Pain Relevance 0.29
Although GD1a, GD1b and GQ1b gangliosides appeared to be as effective as GM1 when tested at microM concentrations for 15 min, tests at lower concentrations, shorter periods, and/or at lower temperature (24 degrees vs 34 degrees C), showed that they were significantly less effective than GM1.
Gene_expression (gangliosides) of GQ1b
5) Confidence 0.01 Published 1991 Journal Brain Res. Section Abstract Doc Link 1685937 Disease Relevance 0.65 Pain Relevance 1.10

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox